Compare OLN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | IRON |
|---|---|---|
| Founded | 1892 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | OLN | IRON |
|---|---|---|
| Price | $20.70 | $77.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $23.93 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 3.4M | 526.3K |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,780,800,000.00 | N/A |
| Revenue This Year | $2.92 | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $17.66 | $30.82 |
| 52 Week High | $32.88 | $99.50 |
| Indicator | OLN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 46.80 |
| Support Level | $22.29 | $74.42 |
| Resistance Level | $24.79 | $82.26 |
| Average True Range (ATR) | 1.11 | 3.78 |
| MACD | -0.30 | 0.72 |
| Stochastic Oscillator | 20.98 | 65.51 |
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.